Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Old API Wind-down Ltd - Ordinary Shares ARLZQ

"Old API Wind-down Ltd, formerly Aralez Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in the acquisition, development, and commercialization of products primarily in cardiovascular, pain management and other specialty areas. Its key products include Fiorinal, Proferrin, Fibricor, Uracyst and Neovisc, Cambia and other marketed products. The company currently... see more

OTCPK:ARLZQ - Post Discussion

Old API Wind-down Ltd - Ordinary Shares > CEO Purchased Half Million Shares!
View:
Post by snootchybootchy on Mar 18, 2017 4:18am

CEO Purchased Half Million Shares!

Mr. Adams purchased half a million shares in the open market on wednesday.  Other insiders purchased a total of 90,000 shares.  This is what I wanted to see!  I knew Mr. Adams would do something to support the share price.

Aralez shot up 9% in after-hours trading.

User image
Comment by GoldenDilemma on Mar 18, 2017 8:55am
Has very little long term viability. If it does cause some upward movement on Monday or a bit through next week, once the day traders or other baggies dry up, all the shorts do is come back in. Doesn't chage the fundamentals which will continued to be scrutinized until ARLZ is derisked via positive Q's.  Don't forget that Adams was buying in the $6+ zone. How was that support?
Comment by kuatolives on Mar 18, 2017 1:51pm
-I wouldn't put too much stock in what Goldman has to say. This is the same bozo who thought it prudent to trade Tribute growth for a single bet on Yosprala that didn't pay off (yet?). He's also sold off more than half his stake so it goes to show you how committed he is.  -Deerfield being committed today doesn't mean they'll be committed tomorrow if the market discounts ...more  
Comment by snootchybootchy on Mar 18, 2017 3:52pm
kuatolives/goldendilemma, you fellas make good points but I'm really looking at Aralez in a different way.  My feeling is that the market has declared Yosprala a failure much too early.  There had been only five months of sales data since the drug was approved, and that duration spanned the Christmas/New Years holiday to boot.  Five months is much too early to start forecasting ...more  
Comment by kuatolives on Mar 18, 2017 6:10pm
You could very well be right, but as it's been mentioned on this board a few times over the last couple of years, ARLZ did everything they said they were going to do without any slipups, and the market still didn't respond positively; however, the first time there was a blip the market crushed the stock. The way I see it, ARLZ is probably on the 3-strike rule with strike 1 happening with ...more